Staphylococcus aureus vaccine - Jiangsu Province Centers for Disease Control and Prevention

Drug Profile

Staphylococcus aureus vaccine - Jiangsu Province Centers for Disease Control and Prevention

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jiangsu Provincial Center for Disease Control and Prevention
  • Developer Chengdu Olymvax Biopharmaceuticals; Jiangsu Provincial Center for Disease Control and Prevention; Third Military Medical University
  • Class Bacterial vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase 0 Staphylococcal infections

Most Recent Events

  • 05 Jul 2016 Preclinical for Staphylococcal infections (Prevention) in China (NCT02820883) before July 2016
  • 05 Jul 2016 Jiangsu Province Centers for Disease Control and Prevention plans a phase 0 trial for Staphyloccocal infections in China (Prevention) (NCT02820883)
  • 01 Jun 2016 Phase-0 for Staphylococcal infections (Prevention) in China (unspecified route) (NCT02820883)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top